Benzinga | Sep 11, 2020 09:08AM EDT

Natera Reports Medicare Admin. Contractor For Northern California, Noridian, Finalized Final Local Coverage ARticle To Provide Medicare Benefits For Serial Use Of Signatera Molecular Residual Disease Test In Patients With History Of Colorectal Cancer

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide Medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with a history of colorectal cancer.



The Noridian article is in line with the positive coverage determination issued by the CMS Molecular Diagnostics (MOLDX) program last week via Palmetto GBA and shares the same effective date of October 18th, 2020.